RNA-seq of danshen injection, astaxanthin and diosmetin for the treatment of anthracycline-induced cardiotoxicity in H9c2 cardiomyocytes
Doxorubicin (DOX) and other anthracyclines are effective chemotherapeutic agents, however, their use is influenced by the risk of cardiotoxicity. We still have an incomplete understanding of the cardiomyocyte protective pathways activated after anthracycline-induced cardiotoxicity (AIC).Danshen injection (DSI), astaxanthin (AXT) and diosmetin (DMT) are effective in the treatment of cardiovascular diseases, but the mechanism of protection against adriamycin-induced cardiotoxicity is unclear. Here, we performed RNA-seq screening in H9c2 cardiomyocytes to determine the potential protective mechanisms of Danshen injection, astaxanthin and diosmetin against AIC. Overall design: To investigate the therapeutic effects of danshen injection, astaxanthin and diosmetin, respectively, in  anthracycline-induced cardiotoxicity, we divided cultured H9c2 cells into five groups:a control group treated with PBS, a model group exposed to 2µM DOX, a treatment group subjected to 2µM DOX in combination with 50µL DSI diluted 1/20 in culture volume, a treatment group subjected to 2µM DOX in combination with 5µM AXT and a treatment group subjected to 2µM DOX in combination with 10µM DMT. Each group consisted of three samples, with DOX added after 4 hours of DSI, AXT an DMT  treatment. The cells were harvested 24 hours after DOX treatment, then we performed gene expression profiling analysis using data obtained from RNA-seq. Comparative gene expression profiling analysis of RNA-seq data.